Weathering the storm when the end of the road is near: A qualitative analysis of supportive care needs during CAR T‐cell therapy in pediatrics
- 12 June 2024
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (9) , e31092
Abstract
Background: Chimeric antigen receptor (CAR) T‐cell therapy provides promising outcomes in relapsed/refractory B acute lymphoblastic leukemia (ALL), yet still carries high toxicity rates and relatively poor long‐term survival. Efficacy has yet to be demonstrated in other diagnoses while toxicity and risk profiles remain formidable. To date, treatment‐related symptom burden is gleaned from clinical trial toxicity reports; the patient perspective remains understudied.Methods: English‐ or Spanish‐speaking patients (ages 8–25 years) undergoing CAR T‐cell therapy for any malignancy and their primary caregivers were recruited from Seattle Children's Hospital (SCH), St. Jude Children's Research Hospital (SJCRH), and the Pediatric Oncology Branch of the National Cancer Institute (NCI). Both patient and caregiver completed semi‐structured dyadic interviews 3 months post treatment. We used directed content analysis for codebook development and thematic network analysis for inductive qualitative analysis.Results: Twenty families completed interviews (13 patients, 15 parents). Patients were a median age 16.5 years, predominantly female (65%), White (75%), and diagnosed with ALL (75%). Global themes included “A clear decision,” “Coping with symptoms,” and “Unforeseen psychosocial challenges.” When families were asked to describe the “most challenging part of treatment,” most described “the unknown.” Most reported “the symptoms really weren't that bad,” even among patients hospitalized for severe toxicity events. Fatigue, pain, and nausea were the most prevalent symptoms. Importantly, only one family would have chosen a different therapy, if given another opportunity.Conclusions: Although physical symptoms were largely tolerable, recognizing supportive care opportunities remains imperative, particularly psychosocial concerns.Keywords
All Related Versions
Funding Information
- National Institutes of Health
- American Lebanese Syrian Associated Charities
- National Heart, Lung, and Blood Institute
- Conquer Cancer Foundation
- St. Baldrick's Foundation
This publication has 33 references indexed in Scilit:
- Precision medicine’s new frontier: integrating palliative care at the right timeESMO Open, 2023
- Mixed‐methods analysis of decisional regret in parents following a child's death from cancerPediatric Blood & Cancer, 2023
- Care experiences that foster trust between parents and physicians of children with cancerPediatric Blood & Cancer, 2020
- Psychosocial care for children receiving chimeric antigen receptor (CAR) T‐cell therapyPediatric Blood & Cancer, 2020
- Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2020
- Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and OpportunitiesTransplantation and Cellular Therapy, 2019
- Palliative Care as a Standard of Care in Pediatric OncologyPediatric Blood & Cancer, 2015
- Standards for the Psychosocial Care of Children With Cancer and Their Families: An Introduction to the Special IssuePediatric Blood & Cancer, 2015
- Test of a conceptual model of uncertainty in children and adolescents with cancerResearch in Nursing & Health, 2010
- Linking Clinical Variables With Health-Related Quality of LifeJAMA, 1995